In late 2026, the industry is pivoting toward "Immuno-Oncology (IO) Preparation." This year, a radical new wave of R&D is focused on the impending 2028 patent expirations of blockbuster PD-1 inhibitors like Keytruda and Opdivo. This innovation is a primary driver for the market, as these "Checkpoint Inhibitors" currently represent the largest segment of oncology spending worldwide. Using...